Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

Moreover, most previously-untreated NSCLC patients treated with Keytruda do so in combination with chemo, so the new data – if added to Libtayo's label – could allow the drug to directly ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Philogen SpA reported a significant increase in its full-year 2024 revenues, reaching €77.5 million, a threefold rise compared to the previous year. Despite the impressive financial performance ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Philogen SpA reported a significant increase in its full-year 2024 revenues, reaching €77.5 million, a threefold rise compared to the previous year. Despite the impressive financial performance, the ...

The approval was based on results from the eNRGy study, an open-label trial involving 94 adults with either NRG1 fusion–positive NSCLC or pancreatic cancer who experienced progression after standard ...

Today's label printers range from small desktop units for file-folder paper labels to industrial-grade ones for labeling cables with plastic strips. Here's how to pick the right labeler ...